Seth B. Zuckerman

Seth B. Zuckerman

Senior Associate

Accelerating Growth of Great Healthcare Companies.

Seth brings to Safeguard a breadth of experience with stakeholders across the healthcare landscape and a deep knowledge of corporate strategy and finance.

At Safeguard, Seth is responsible for identifying and evaluating new companies and supporting Safeguard’s existing partner companies.

Prior to joining Safeguard, Seth was a Manager at the strategy consultancy Monitor Deloitte, formerly Monitor Group. At Monitor, he advised payers, providers, and pharmaceutical / medical device companies on organic and inorganic growth strategy opportunities. He also has experience working with a healthcare start-up in the anti-microbial space, analyzing investment opportunities at Circle Peak Capital, and advising CEOs of entrepreneurial companies at Next Street Financial.

Seth received an M.B.A. in Finance and Economics and a B.A. in Economics and Political Science from Columbia University.

“Safeguard's partner companies are able to leverage the efficiencies of Safeguard's resources to build strategies, source talent, access influential customers and partners, increase visibility, and much more—enabling them to better capitalize on the growth opportunities presented to them.”

March 7, 2017

Winning the Digital Disruption Game: Answering the ‘CAST’ing Call

This post originally appeared on CIOReview.com on March 6th, 2017.  By: Peter Coffee, VP for Strategic Research, Salesforce and Scott Snyder, Chief Technology and Innovation Officer,…

philadelphia

February 7, 2017

Outside of the Valley, Alternative Markets Attract Investors

Nearly 60 percent of all U.S. venture capital activity is concentrated in the Bay Area, Boston metro, and New York City’s orbit.[1] For some entrepreneurs,…

Cybersecurity Medical Devices

January 26, 2017

Commentary: Postmarket Management of Cybersecurity in Medical Devices

Over the last 18 months, an alarming number of medical device companies’ challenges with data security have been exposed. In 2015, Hospira’s LifeCare PCA3 and…